21
10
150
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T0517 |
Pancreatin
Pancreatic enzymes,pancrelipase,胰酶 |
Others | Others |
Pancreatin (pancrelipase) 是一种含有胰腺消化酶的猪胰腺提取物。 | |||
T79225 |
α-Amylase/α-Glucosidase-IN-3
|
Glucosidase | Metabolism |
α-Amylase/α-Glucosidase-IN-3 (Compound 17) 是一种具有针对α-Amylase和α-Glucosidase的双重抑制活性的化合物,其IC50分别为0.70 μM和1.10 μM。该化合物可应用于II型糖尿病的研究领域。 | |||
T60447 |
α-Amylase-IN-3
|
Others | Others |
α-Amylase-IN-3 (Compound 4) 是α-Amylase 的非竞争性型抑制剂,IC50值为 18.04 μM。α-Amylase-IN-3具有自由基清除活性,对DPPH 和ABTS 的IC50值分别为 16.04 μM 和 16.99 μM。α-Amylase-IN-3 显示出良好的 α-淀粉酶蛋白质-配体相互作用,可能具有抗氧化、抗炎等药理活性,有助于研究糖尿病和氧化应激相关疾病。 | |||
T73745 |
Ethylidene-4-nitrophenyl-a-D-Maltoheptaoside
|
Others | Others |
Ethylidene-4-nitrophenyl-a-D-Maltoheptaoside (EPS; pNP-G7) 作为α-淀粉酶的底物,主要应用于测定α-淀粉酶的活性。 | |||
T80715 |
α-Amylase/α-Glucosidase-IN-6
|
Others | Others |
α-Amylase/α-Glucosidase-IN-6 (compound 5j) 是一种对α-amylase和α-glucosidase具有双重抑制作用的有效化合物,其IC50s分别为17.0 µM和40.1 µM。该化合物还表现出抗高血糖活性。 | |||
T78627 |
Chinese gallotannin
|
Others | Others |
Chinese gallotannin,一种非特异性α-amylase抑制剂,对人唾液α-淀粉酶具有较强的抑制作用,其Ki值为0.82 μg/mL。此化合物可用于糖尿病研究。 | |||
T78359 |
β-Amylase
|
Others | Others |
β-Amylase具有高效的淀粉水解功能,广泛应用于生化实验研究领域。 | |||
T78878 |
α-Amylase/α-Glucosidase-IN-5
|
Glucosidase | Metabolism |
α-Amylase/α-Glucosidase-IN-5 (compound 4l) 是一种同时针对α-葡萄糖苷酶 (Glucosidase) 和α-淀粉酶 (Amylases) 的抑制剂,IC50 值分别为 5.96 μM 和 1.62 μM,显示出潜在的抗糖尿病活性。 | |||
T79402 |
α-Amylase/α-Glucosidase-IN-4
|
Glucosidase | Metabolism |
α-Amylase/α-Glucosidase-IN-4 (compound 5) 是一种针对 α-葡萄糖苷酶 (Glucosidase) 及 α-淀粉酶 (Amylases) 的双效抑制剂,分别展现出 0.15 μM 和 1.10 μM 的IC50s。该化合物展示了其潜在的抗糖尿病活性。 | |||
T74255 |
HPA-IN-1
|
Others | Others |
HPA-IN-1 (Compound 1)为高效、选择性的人类胰腺α淀粉酶(HPA)抑制剂,其对HPA及α-glucosidase的IC50值分别为12.0 μM与410.4 μM。 | |||
T25522 |
Ici 216140
m216140,Ici216140,m 216140,Ici-216140,m-216140 |
Others | Others |
ICI 216140 is a GRP/bombesin receptor 2 antagonist (IC50: 2 nM in vitro). At 2 mg/kg, it can decrease bombesin-stimulated pancreatic amylase secretion in rats. At 1 mM, it has been proved to attenuate bombesin-stimulated increases in blood pressure in rat | |||
T37834 |
G3-CNP
|
Others | Others |
G3-CNP is a colorimetric substrate for α-amylases.1Upon hydrolysis by α-amylases, 2-chloro-4-nitrophenol is released which can be quantified by colorimetric detection at 405 nm as a measure of enzyme activity. G3-CNP has been used to characterize the activity of human pancreatic or salivary amylase. | |||
TP1241 |
Adrenocorticotropic Hormone (ACTH) (18-39), human
ACTH (18-39), human |
||
Adrenocorticotropic Hormone (ACTH) (18-39) is known as the Corticotropin-like Intermediate Lobe Peptide. It stimulates insulin secretion as well as amylase and protein secretion in a dose-dependent manner similar to those of secretin and carbamylcholine. | |||
T36864 |
GRP (human) (trifluoroacetate salt)
|
||
Gastrin-releasing peptide (GRP) is a neuropeptide that stimulates gastrin release. It binds to (Ki = 300 nM) and stimulates amylase secretion in rat pancreatic AR42J cells (EC50 = 0.3 nM). GRP increases proliferation of human liver carcinoma HepG2 and MHCC97H cells but does not affect the proliferation of normal HL-7702 liver cells at a concentration of 1 nM. In vivo, GRP (0.35 nmol/kg/h) increases both pancreatic exocrine secretion and pancreatic polypeptide (PP) release in rats. It dose-depend... | |||
T78376 |
Rimtoregtide
|
||
Rimtoregtide为一多肽化合物,能显著下调急性胰腺炎致血液淀粉酶与脂肪酶水平升高。该化合物在胰腺炎及急性胰腺炎研究中具备潜力。 | |||
T76262L |
Cagrilintide acetate
|
||
Cagrilintide acetate 是一种非选择性的 AMYR/CTR 激动剂和长效酰化淀粉酶类似物。Cagrilintide acetate 以剂量依赖的方式导致食物摄入减少和体重明显下降。Cagrilintide acetate 可用于肥胖症的研究。 | |||
T76461 |
[Nle8] Somatostatin (1-28)
|
||
[Nle8] Somatostatin (1-28)为生长抑素(1-28)的衍生物,其特征在于第8位的甲硫氨酸被正亮氨酸所替代。该化合物能够促使淀粉酶的释放,并增加胰腺腺泡中的环AMP水平。 | |||
T75707 |
BIM-26226
|
||
BIM-26226 是一种胃泌素释放肽,是一种强效选择性的bombesin receptor 拮抗剂。 BIM-26226 抑制 BN 或 GRP 刺激的淀粉酶释放,IC50值在纳摩尔范围内。BIM-26226 可用于癌症研究。 | |||
T79644 |
Antidiabetic agent 2
|
Glucosidase | Metabolism |
Antidiabetic agent 2 (Compound 56) 作为一种葡萄糖摄取促进剂,能有效地抑制DPP-4, PTP-1B, α-淀粉酶和α-葡萄糖苷酶,其IC50s分别达到0.036、0.042、0.241、0.185 μM,表现出显著的降血糖作用。 | |||
T37835 |
2-Chloro-4-nitrophenyl-α-D-glucopyranoside
|
Others | Others |
Carbohydrates conjugated with 2-chloro-4-nitrophenyl (CNP) serve as chromogenic substrates in assays for enzymes that release CNP from the conjugated carbohydrate. For example, CNP-β-D-maltoheptaoside and CNP-α-maltotrioside are chromogenic substrates for α-amylase. 2-Chloro-4-nitrophenyl-α-D-glucopyranoside is a conjugate of CNP and α-D-glucose. The related conjugate between CNP and β-D-glucose, 2-chloro-4-nitrophenyl β-D-glucopyranoside, is used as a chromogenic substrate for glycosyltransfera... | |||
T35669 |
Neuromedin C (trifluoroacetate salt)
|
Others | Others |
Neuromedin C is a bombesin-like neuropeptide that stimulates uterine smooth muscle contraction and the release of gastrin , somatostatin, and amylase in rats. Neuromedin C is a truncated form of gastrin-releasing peptide corresponding to the GRP amino acids 18-27. It inhibits GRP and bombesin binding to rat pancreatic membranes (IC50s = 0.4 and 2.2 nM, respectively), which can be reduced by sodium chloride and guanylyl imidodiphosphate . Neuromedin C induces scratching and mast cell degranulatio... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T19615 |
α-Amylase
|
Amylase | Metabolism |
α-Amylase 是一种能够催化淀粉中 α-1,4-糖苷键水解的水解酶,使淀粉产生葡萄糖、麦芽糖等产物。 | |||
T1136 |
Amylase
Diastase,淀粉酶 |
Others | Others |
Amylase (Diastase) 是由胰腺和唾液腺分泌得到的一种酶,能够将淀粉水解为糖类。它大致可分为 α 亚型、 β 亚型 和 γ 亚型三种亚型。 | |||
TN1788 |
Isookanin
|
Amylase | Metabolism |
Isookanin 在多种疾病领域有研究价值,包括肿瘤,皮疹,蛇和昆虫叮咬,糖尿病,腹泻。它可作为抗病毒剂对抗 HSV 和水痘带状疱疹病毒。它也具有抗氧化特性。 | |||
TN4368 |
Kaempferol-3,7-di-O-β-glucoside
Kaempferol 3,7-di-O-glucoside |
Glucosidase; Amylase | Metabolism |
Kaempferol-3,7-di-O-β-glucoside (Kaempferol 3,7-diglucoside) 是一种来自 Morettia philaena 的黄酮醇,对 α-淀粉酶 (α-amylase)、α-葡萄糖苷酶 (α-glucosidase) 和乙酰胆碱酯酶 (Acetylcholinesterase) 具有抑制作用。Kaempferol-3,7-di-O-β-glucoside 具有神经保护活性,可减缓分化神经元细胞 SH-SY5Y 免受 Amyloid β 肽诱导的损伤。Kaempferol-3,7-di-O-β-glucoside 可用于研究阿尔茨海默氏症类的神经系统疾病。 | |||
T2S0731 |
Trilobatin
三叶苷,三叶甙,P-Phlorizin |
Amylase | Metabolism |
Trilobatin (P-Phlorizin) 是源自Lithocarpus polystachyusRehd 的甜味剂,是一种HIV-1抑制剂,靶向 Gp41 包膜蛋白,具有神经保护作用。它还是SGLT1/2抑制剂,可选择性诱导人肝母细胞瘤细胞增殖。 | |||
T3S0013 |
Ethyl trans-caffeate
咖啡酸乙酯,Ethyl caffeate,Caffeic Acid Ethyl Ester |
Others | Others |
Ethyl trans-caffeate (Caffeic Acid Ethyl Ester) 具有抗炎作用。 它是一种有前途的天然化合物,未来在慢性肝病中的应用。它是一种有效的化学预防化合物,可防止因太阳紫外线照射引起的皮肤癌变。它是与人胰腺α-淀粉酶复合的代表性抑制剂的高分辨率结构。 它强烈抑制 JB6 Cl41细胞的肿瘤转化,无毒性。 PI3K、ERK1/2 和 p38 激酶活性在体外通过与 HOEC 直接结合而受到抑制。 | |||
T40769 |
Maltooctaose
|
Others | Others |
Maltooctaose, a defined maltooligosaccharide with a specific length, can be enzymatically synthesized using Pyrococcus furiosus thermostable amylase (PFTA). | |||
TN4010 |
Erythrocentaurin
|
Antifection | Microbiology/Virology |
Erythrocentaurin has antibacterial activity; it also exhibits a concentration-dependent α-amylase inhibition (IC(50) 1.67 ± 0.28 mg/mL). | |||
T75701 |
8,3′,4′-Trihydroxyflavone-7-O-β-D-glucopyranoside
|
Others | Others |
8,3′,4′-Trihydroxyflavone-7-O-β-D-glucopyranoside (Compound 3) 是一种可以从Bidens bipinnata 分离得到的天然产物。8,3′,4′-Trihydroxyflavone-7-O-β-D-glucopyranoside 在 0.556 mg/mL 时对α-amylase 有 22% 的抑制作用。 | |||
T75492 |
Ellipyrone A
|
Others | Others |
Ellipyrone A为一种大环肽,对二肽基肽酶 4 (dipeptidyl peptidase-4: IC50=0.35 mM) 显示出抑制活性,并对α-葡萄糖苷酶 (IC50=0.74 mM) 及α-淀粉酶 (IC50=0.59 mM) 也具有明显的抑制效果,表现出其抗碳水化合物分解的性能。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-03921 |
Alpha amylase/AMY2A Protein, Rhesus, Recombinant (His)
AMY2A,amylase, α 2A<... |
Rhesus | HEK293 Cells |
Alpha amylase/AMY2A Protein, Rhesus, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 57.2 kDa and the accession number is H9EX43. | |||
TMPY-00529 |
Alpha amylase/AMY2A Protein, Rhesus, Recombinant (hFc)
amylase, alpha 2A |
Rhesus | HEK293 Cells |
Alpha amylase/AMY2A Protein, Rhesus, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 82.8 kDa and the accession number is H9EX43. | |||
TMPY-03107 |
Alpha amylase/AMY2A Protein, Human, Recombinant (His)
amylase, α 2A (pancre |
Human | HEK293 Cells |
Alpha amylase/AMY2A Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 57.3 kDa and the accession number is P04746. | |||
TMPY-00503 |
Beta Amylase/AMY2B Protein, Human, Recombinant (His)
AMY2,amylase, alpha<... |
Human | HEK293 Cells |
Beta Amylase/AMY2B Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 57.3 kDa and the accession number is P19961-1. | |||
TMPY-00340 |
Beta Amylase/AMY2B Protein, Human, Recombinant (hFc)
β Amylase/AMY2B,AMY2,HX<... |
Human | HEK293 Cells |
Beta Amylase/AMY2B Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 82.4 kDa and the accession number is P19961-1. | |||
TMPH-00079 |
Beta-amylase 3, chloroplastic Protein, Arabidopsis thaliana, Recombinant (His)
BAM3,CTBMY,1,4-alpha-D-gluca<... |
Arabidopsis thaliana | E. coli |
Beta-amylase activity. No alpha-amylase activity. Involved in cold resistance. Mediates the accumulation of maltose upon freezing stress, thus contributing to the protection of the photosynthetic electron transport chain. Plays a role in the circadian-regulated starch degradation and maltose metabolism in chloroplasts, especially at night. More active on phosphorylated glucan. Interacts directly with starch or other alpha-1,4-glucan. | |||
TMPH-00078 |
Beta-amylase 1, chloroplastic Protein, Arabidopsis thaliana, Recombinant (His & Myc)
1,4-alpha-D-glucan malto... |
Arabidopsis thaliana | E. coli |
Beta-amylase activity. Can use p-nitrophenyl maltopentaoside (PNPG5) as substrate only in reduced form. Can play a minor role in the starch degradation and maltose metabolism in chloroplasts during the night. More active on phosphorylated glucan. Interacts directly with starch or other alpha-1,4-glucan. Beta-amylase 1, chloroplastic Protein, Arabidopsis thaliana, Recombinant (His & Myc) is expressed in E. coli expression system with N-10xHis and C-Myc tag. The predicted molecular weight is 41.7 ... | |||
TMPH-01636 |
MGAM Protein, Human, Recombinant (aa 960-1853, His)
Alpha-1,4-glucosidase,Ma... |
Human | Baculovirus Insect Cells |
May serve as an alternate pathway for starch digestion when luminal alpha-amylase activity is reduced because of immaturity or malnutrition. May play a unique role in the digestion of malted dietary oligosaccharides used in food manufacturing. | |||
TMPH-03607 |
HOE-467A Protein, Streptomyces tendae, Recombinant (His & Myc & SUMO)
Tendamistat,Alpha-a<... |
Streptomyces tendae | E. coli |
Inhibits mammalian alpha-amylases specifically but has no action on plant and microbial alpha-amylases. Forms a tight stoichiometric 1:1 complex with alpha-amylase. HOE-467A Protein, Streptomyces tendae, Recombinant (His & Myc & SUMO) is expressed in E. coli expression system with N-10xHis-SUMO and C-Myc tag. The predicted molecular weight is 28.0 kDa and the accession number is P01092. | |||
TMPH-01635 |
MGAM Protein, Human, Recombinant (aa 87-954, His)
MGAM,Maltase-glucoamyl |
Human | Baculovirus Insect Cells |
May serve as an alternate pathway for starch digestion when luminal alpha-amylase activity is reduced because of immaturity or malnutrition. May play a unique role in the digestion of malted dietary oligosaccharides used in food manufacturing. MGAM Protein, Human, Recombinant (aa 87-954, His) is expressed in Baculovirus insect cells with C-6xHis tag. The predicted molecular weight is 101.1 kDa and the accession number is O43451. | |||
TMPK-01419 |
Peptide Ready HLA-A*03:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,HLA-A*02:01,Peptide Ready |
Human | HEK293 Cells |
Peptide Ready HLA-A*03:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*03:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01426 |
Peptide Ready HLA-A*11:01&B2M Monomer Protein, Human, MHC (His & Avi)
HLA-A*02:01,Peptide Ready,MHC |
Human | HEK293 Cells |
Peptide Ready HLA-A*11:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*11:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01421 |
Peptide Ready HLA-A*02:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
HLA-A*02:01,MHC,Peptide Ready |
Human | HEK293 Cells |
HLA-A*02:01&B2M&Peptide ready Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*02:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01420 |
Peptide Ready HLA-A*03:01&B2M Monomer Protein, Human, MHC (His & Avi)
Peptide Ready,MHC,HLA-A*02:01 |
Human | HEK293 Cells |
Peptide Ready HLA-A*03:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*03:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01410 |
Peptide Ready HLA-A*24:02&B2M Monomer Protein, Human, MHC (His & Avi)
HLA-A,MHC,Peptide Ready |
Human | HEK293 Cells |
Peptide Ready HLA-G&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-G. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01422 |
Peptide Ready HLA-A*02:01&B2M Monomer Protein, Human, MHC (His & Avi)
Peptide Ready,MHC,HLA-A*02:01 |
Human | HEK293 Cells |
Peptide Ready HLA-A*02:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*02:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01425 |
Peptide Ready HLA-A*11:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,HLA-A*02:01,Peptide Ready |
Human | HEK293 Cells |
Peptide Ready HLA-A*11:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*11:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01415 |
APC-equivalent Peptide Ready HLA-A*02:01&B2M Tetramer Protein, Human, MHC (His)
Peptide Ready,HLA-A*02:01,MHC |
Human | HEK293 Cells |
Peptide Ready HLA-A*02:01&B2M Tetramer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*02:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01409 |
Peptide Ready HLA-A*24:02&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
Peptide Ready,MHC,HLA-A |
Human | HEK293 Cells |
Peptide Ready HLA-G&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-G. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01510 |
HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi)
NS,NS3,KRAS2,RASK2,MHC,RALD,K-R |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01463 |
HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi)
C-K-RAS,KI-RAS,KRAS1,K-RA |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01429 |
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated
MHC,K-Ras 2,NS,K-RAS4A,KRA |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01500 |
HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Monomer Protein, Human, MHC (His & Avi)
CTAG1,CT6.1,CTAG1B,LAGE2A |
Human | HEK293 Cells |
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy. | |||
TMPK-01473 |
HLA-A*24:02&B2M&MAGE-A3 (IMPKAGLLI) Monomer Protein, Human, MHC (His & Avi), Biotinylated
CT1.3,MAGE-3,MZ2-D,MZ2D,HLA-A2402... |
Human | HEK293 Cells |
Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa. | |||
TMPK-01518 |
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi)
MHC,NS,KRAS1,K-RAS2A,GTPa |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01527 |
HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)
NS,RALD,C-K-RAS,RASK2,K-RA |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01408 |
HLA-A*02:01&B2M&KRAS G12V (KLVVVGAVGV) Monomer Protein, Human, MHC (His & Avi), Biotinylated
RALD,KRAS1,KRAS2,K-RAS2B... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01433 |
HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Tetramer Protein, Human, MHC (His & Avi)
GTPase Kras,NS3,K-Ras 2,K-RA<... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01455 |
HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer Protein, Human, MHC (His & Avi)
OIP4,PRAME,OIP-4,MAPE |
Human | HEK293 Cells |
PRAME (PReferentially expressed Antigen in MElanoma) is a melanoma-associated antigen expressed in cutaneous and ocular melanomas and some other malignant neoplasms, while its expression in normal tissue and benign tumors is limited. | |||
TMPK-01401 |
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
MHC,CFC2,K-Ras 2,RALD,K-RAS4A... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01488 |
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi)
K-RAS4A,MHC,GTPase Kras,... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01442 |
HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled
HLA-A,P53,TP53,LFS1,MHC,BCC7,TRP53,FLJ9294... |
Human | HEK293 Cells |
p53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein. p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth. | |||
TMPK-01445 |
HLA-A*02:01&B2M&MAGE-A1 (KVLEYVIKV) Monomer Protein, Human, MHC (His & Avi), Biotinylated
CT1.1,MAGE1,MAGE-1,MAGE-A |
Human | HEK293 Cells |
MAGE-A1 belongs to the chromosome X-clustered genes of cancer-testis antigen family and is normally expressed in the human germ line but is also overexpressed in various tumors. | |||
TMPK-01493 |
HLA-A*01:01&B2M&MAGE-A3 (EVDPIGHLY) Tetramer Protein, Human, MHC (His & Avi)
MZ2-D,Melanoma-associate... |
Human | HEK293 Cells |
Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa. | |||
TMPK-01477 |
HLA-A*02:01&B2M&AFP (FMNKFIYEI) Monomer Protein, Human, MHC (His & Avi), Biotinylated
HPAFP,FETA,Alpha-1-fetop... |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
TMPK-01458 |
HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi)
K-Ras 2,GTPase Kras,KRAS... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01539 |
HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer Protein, Human, MHC (His & Avi), Biotinylated
CTAG1B,CT6.1,MY-ESO-1,LAGE2A,NY-E... |
Human | HEK293 Cells |
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy. | |||
TMPK-01529 |
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (His & Avi)
K-RAS4A,KRAS1,MHC,K-RAS2... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01484 |
HLA-A*02:03&B2M&AFP (FMNKFIYEI) Monomer Protein, Human, MHC (His & Avi)
HPAFP,FETA,AFP,AFPD,... |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
TMPK-01449 |
HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer Protein, Human, MHC (E. coli, His & Avi)
MHC,CT6.1,CTAG1,LAGE-2,MY-ESO-1,NY-ESO-1,E... |
Human | E. coli |
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy. | |||
TMPK-01480 |
HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
IAP4,Survivin,API4,BIRC5,MHC,MHC I,EPR-1,s... |
Human | HEK293 Cells |
Survivin (also known as BIRC5) is an evolutionarily conserved eukaryotic protein that is essential for cell division and can inhibit cell death. Normally it is only expressed in actively proliferating cells, but is upregulated in most, if not all cancers; consequently, it has received significant attention as a potential oncotherapeutic target. | |||
TMPK-01404 |
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated
NS,KRAS,KRAS1,KRAS2,MHC,RA |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01519 |
HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer Protein, Human, MHC (His & Avi)
MHC,FETA,AFP,Alpha-feto,... |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
TMPK-01470 |
HLA-A*02:01&B2M&MAGE-A4 or MAGE-A8 (KVLEHVVRV) Monomer Protein, Human, MHC (His & Avi)
MAGE-A4 or MAGE-A8,M... |
Human | HEK293 Cells |
MAGE-A4 and MAGE-A8 are type I membes of the melanoma associated antigen (MAGE) family. The MAGE family is a large, highly conserved group of proteins that share a common MAGE homology domain. Both MAGE-A4 and MAGE-A8 antigen-presenting peptides can be presented by HLA-A*02:01. | |||
TMPK-01481 |
HLA-A*24:02&B2M&Survivin 2B (AYACNTSTL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
svn 2B,svn-2B,Survivin-2B |
Human | HEK293 Cells |
Survivin-2B, a known splice variant of survivin, has been reported to promote cell death in some cancer cells, although it keeps prosurvival function in others.survivin-2B promoted autophagy and further regulated cell death by accumulating and stabilizing IKK alpha in the nucleus. | |||
TMPK-01494 |
HLA-A*01:01&B2M&CT83 (NTDNNLAVY) Tetramer Protein, Human, MHC (His & Avi)
HLA-A,HLA-A*0101,HLA... |
Human | HEK293 Cells |
Cancer/testis antigens 83 (CT83), also called KK-LC-1 or CXorf61, recognized by cytotoxic T lymphocytes (CTL), has become a promising target for immunotherapy. | |||
TMPK-01444 |
HLA-A*02:01&B2M&MAGE-A1 (KVLEYVIKV) Tetramer Protein, Human, MHC (His & Avi)
MZ2-E,MAGE1A,MAGE-1 anti... |
Human | HEK293 Cells |
MAGE-A1 belongs to the chromosome X-clustered genes of cancer-testis antigen family and is normally expressed in the human germ line but is also overexpressed in various tumors. | |||
TMPK-01530 |
HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,LMP-2,PSMB9,LMP2,Macropain cha |
Human | HEK293 Cells |
The immunoproteasome, having been linked to neurodegenerative diseases and hematological cancers, has been shown to play an important role in MHC class I antigen presentation. The development of molecular probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome,LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor, implicating an important role of LMP2 in regulating cell growth of ma... | |||
TMPK-01434 |
HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Tetramer Protein, Human, MHC (His & Avi)
RASK2,CFC2,GTPase Kras,KRA |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01525 |
HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
CFC2,RALD,K-Ras 2,MHC,C-K-RAS,NS3... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
------------------------ 更多 ------------------------ |